234 related articles for article (PubMed ID: 29408293)
21. Tolerability of risk: A commentary on the nitrosamine contamination issue.
Elder DP; Johnson GE; Snodin DJ
J Pharm Sci; 2021 Jun; 110(6):2311-2328. PubMed ID: 33705731
[TBL] [Abstract][Full Text] [Related]
22. Improved in silico prediction of carcinogenic potency (TD50) and the risk specific dose (RSD) adjusted Threshold of Toxicological Concern (TTC) for genotoxic chemicals and pharmaceutical impurities.
Contrera JF
Regul Toxicol Pharmacol; 2011 Feb; 59(1):133-41. PubMed ID: 20933038
[TBL] [Abstract][Full Text] [Related]
23. Lesson Learnt from Recall of Valsartan and Other Angiotensin II Receptor Blocker Drugs Containing NDMA and NDEA Impurities.
Charoo NA; Ali AA; Buha SK; Rahman Z
AAPS PharmSciTech; 2019 Apr; 20(5):166. PubMed ID: 30989447
[TBL] [Abstract][Full Text] [Related]
24. Chemicals used in the rubber industry.
Fishbein L
Sci Total Environ; 1991 Jan; 101(1-2):33-43. PubMed ID: 2057768
[TBL] [Abstract][Full Text] [Related]
25. Health related guide values for drinking-water since 1993 as guidance to assess presence of new analytes in drinking-water.
Dieter HH
Int J Hyg Environ Health; 2014 Mar; 217(2-3):117-32. PubMed ID: 23820379
[TBL] [Abstract][Full Text] [Related]
26. Strategies for the identification, control and determination of genotoxic impurities in drug substances: a pharmaceutical industry perspective.
Raman NV; Prasad AV; Ratnakar Reddy K
J Pharm Biomed Anal; 2011 Jun; 55(4):662-7. PubMed ID: 21193280
[TBL] [Abstract][Full Text] [Related]
27. Characterization and validation of an in silico toxicology model to predict the mutagenic potential of drug impurities.
Valerio LG; Cross KP
Toxicol Appl Pharmacol; 2012 May; 260(3):209-21. PubMed ID: 22426359
[TBL] [Abstract][Full Text] [Related]
28. In silico approaches to predicting cancer potency for risk assessment of genotoxic impurities in drug substances.
Bercu JP; Morton SM; Deahl JT; Gombar VK; Callis CM; van Lier RB
Regul Toxicol Pharmacol; 2010; 57(2-3):300-6. PubMed ID: 20363275
[TBL] [Abstract][Full Text] [Related]
29. Hydroquinone: an evaluation of the human risks from its carcinogenic and mutagenic properties.
McGregor D
Crit Rev Toxicol; 2007; 37(10):887-914. PubMed ID: 18027166
[TBL] [Abstract][Full Text] [Related]
30. Special endpoint and product specific considerations in pharmaceutical acceptable daily exposure derivation.
Gould J; Callis CM; Dolan DG; Stanard B; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S79-93. PubMed ID: 27233924
[TBL] [Abstract][Full Text] [Related]
31. Comparison of carcinogenic and in vivo genotoxic potency estimates.
Sanner T; Dybing E
Basic Clin Pharmacol Toxicol; 2005 Feb; 96(2):131-9. PubMed ID: 15679476
[TBL] [Abstract][Full Text] [Related]
32. Carcinogenicity categorization of chemicals-new aspects to be considered in a European perspective.
Bolt HM; Foth H; Hengstler JG; Degen GH
Toxicol Lett; 2004 Jun; 151(1):29-41. PubMed ID: 15177638
[TBL] [Abstract][Full Text] [Related]
33. Origin of the TTC values for compounds that are genotoxic and/or carcinogenic and an approach for their re-evaluation.
Boobis A; Brown P; Cronin MTD; Edwards J; Galli CL; Goodman J; Jacobs A; Kirkland D; Luijten M; Marsaux C; Martin M; Yang C; Hollnagel HM
Crit Rev Toxicol; 2017 Sep; 47(8):705-727. PubMed ID: 28510487
[TBL] [Abstract][Full Text] [Related]
34. The application of structure-based assessment to support safety and chemistry diligence to manage genotoxic impurities in active pharmaceutical ingredients during drug development.
Dobo KL; Greene N; Cyr MO; Caron S; Ku WW
Regul Toxicol Pharmacol; 2006 Apr; 44(3):282-93. PubMed ID: 16464524
[TBL] [Abstract][Full Text] [Related]
35. The use of dose-response data in a margin of exposure approach to carcinogenic risk assessment for genotoxic chemicals in food.
Benford DJ
Mutagenesis; 2016 May; 31(3):329-31. PubMed ID: 26297741
[TBL] [Abstract][Full Text] [Related]
36. Identification, control strategies, and analytical approaches for the determination of potential genotoxic impurities in pharmaceuticals: a comprehensive review.
Reddy AV; Jaafar J; Umar K; Majid ZA; Aris AB; Talib J; Madhavi G
J Sep Sci; 2015 Mar; 38(5):764-79. PubMed ID: 25556762
[TBL] [Abstract][Full Text] [Related]
37. Use of less-than-lifetime (LTL) durational limits for nitrosamines: Case study of N-Nitrosodiethylamine (NDEA).
Bercu JP; Masuda-Herrera M; Johnson G; Czich A; Glowienke S; Kenyon M; Thomas R; Ponting DJ; White A; Cross K; Waechter F; Rodrigues MAC
Regul Toxicol Pharmacol; 2021 Jul; 123():104926. PubMed ID: 33862169
[TBL] [Abstract][Full Text] [Related]
38. Characterization of false positive, contaminant-driven mutagenicity in impurities associated with the sotorasib drug substance.
Coppi A; Davies R; Wegesser T; Ishida K; Karmel J; Han J; Aiello F; Xie Y; Corbett MT; Parsons AT; Monticello TM; Minocherhomji S
Regul Toxicol Pharmacol; 2022 Jun; 131():105162. PubMed ID: 35331777
[TBL] [Abstract][Full Text] [Related]
39. Advancing toxicology in RiskMAPP: setting ADEs based on the subsequent drug substance.
Bercu JP; Sharnez R; Dolan DG
Regul Toxicol Pharmacol; 2013 Feb; 65(1):157-61. PubMed ID: 22921793
[TBL] [Abstract][Full Text] [Related]
40. Toxicity assessment strategies, data requirements, and risk assessment approaches to derive health based guidance values for non-relevant metabolites of plant protection products.
Dekant W; Melching-Kollmuss S; Kalberlah F
Regul Toxicol Pharmacol; 2010 Mar; 56(2):135-42. PubMed ID: 19883711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
